2,115 press releases in English indexed under biotech & pharma.
Initiation of patient dosing marks significant clinical development milestone for Nu-3 and Lakewood-Amedex Biotherapeutics' proprietary Bisphosphocin® antimicrobial platform Topline data expected in the first quarter of 2027 SARASOTA, Fla., Sept. 24, 2026 -- Lakewood-Amedex...
Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP)
Montreal Heart Institute Joins Multinational Study Evaluating a Self-Administered 70 mg Repeat-Dose Regimen of Etripamil Montreal Heart Institute Joins Multinational Study Evaluating a Self-Administered 70 mg Repeat-Dose Regimen of Etripamil
Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) approval of Onswik™ (insulin efsitora alfa-gobe), a once-weekly...
Lupus nephritis R&D is shifting toward targeted B-cell, complement, and off-the-shelf cell therapies, opening partnership and licensing opportunities across novel treatment platforms Lupus nephritis R&D is shifting toward targeted B-cell, complement, and off-the-shelf cell therapies, opening partnership and licensing opportunities across novel treatment platforms
Rising cancer incidence and R&D investment are expanding oncology trials. AI can improve recruitment, trial design and data management, while partnerships and novel therapies spur competition. Rising cancer incidence and R&D investment are expanding oncology trials. AI can improve recruitment, trial design and data management, while partnerships and novel therapies spur competition.
Expanding CAR-T and bispecific use is increasing CRS cases, creating opportunities in early diagnosis, preventive immunomodulators, outpatient care and biosimilar IL-6 therapies. Expanding CAR-T and bispecific use is increasing CRS cases, creating opportunities in early diagnosis, preventive immunomodulators, outpatient care and biosimilar IL-6 therapies.
Rising surgeries and opioid safety concerns are accelerating multimodal, non-opioid pain care, creating opportunities for safer parenteral drugs and novel delivery systems. Rising surgeries and opioid safety concerns are accelerating multimodal, non-opioid pain care, creating opportunities for safer parenteral drugs and novel delivery systems.
AI adoption is accelerating drug discovery, precision medicine, diagnostics and clinical trials, fueled by expanding health data, software demand and pharma-tech partnerships AI adoption is accelerating drug discovery, precision medicine, diagnostics and clinical trials, fueled by expanding health data, software demand and pharma-tech partnerships
OXFORD, United Kingdom and BURLINGTON, Mass., Sept. 24, 2026 -- Scancell Holdings plc (AIM: SCLP) (“Scancell”, or the “Company”), a late-stage clinical immuno-oncology company developing active immunotherapies designed to enhance anti-tumor immune responses in difficult-to-treat cancers, announced today that, further to its announcement on 23 July 2026 regarding the planned merger with Neuphoria Therapeutics Inc. (“Neuphoria”) and financing to conduct the registrational Phase 3 study for iSCIB1+ and a proposed listing on Nasdaq (the “Merger and Financing Announcement”), it has entered into a loan agreement (the “Loan Agreement”) with certain funds and accounts managed by BlackRock (the “Lender”), for a loan facility of up to US$25,000,000 (the “Loan Facility”).
Geneva, Switzerland, September 24, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its 2026 Half-Year and Second Quarter financial results on September 28, 2026. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) on September 28, 2026.
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 23, 2026 -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology (“ESMO”) Congress 2026, taking place on October 23-27, 2026, in Madrid, Spain.